Hofseth BioCare ASA has published peer-reviewed clinical data showing its salmon protein hydrolysate ProGo® delivered measurable GLP-1 improvements and lean muscle mass gains in overweight adults — outcomes that a protein-matched whey supplement failed to replicate over the same period.
The randomised, double-blind, active-controlled pilot study, appearing in the international scientific journal Biomedicines, tracked participants across 56 days of daily ProGo® supplementation. Researchers reported improvements across multiple biological markers tied to metabolic health and healthy ageing. The whey control group, matched for total protein intake, did not show equivalent results, a finding the company says underscores the functional differentiation of marine-derived hydrolysates versus conventional dairy protein.
Why the Data Matters
The GLP-1 signal is commercially significant. Glucagon-like peptide-1 agonists have reshaped the pharmaceutical weight-management market, and ingredient suppliers across the food and beverage sector are racing to identify bioactive compounds that can stimulate endogenous GLP-1 secretion through diet. A clinically validated marine protein with that mechanism of action positions Hofseth BioCare in a rapidly expanding functional ingredient category that spans sports nutrition, healthy-ageing formats, and medical nutrition.
The lean muscle mass finding adds a second commercial hook. Sarcopenia prevention has emerged as a priority formulation target in the premium protein segment, particularly for products aimed at adults over 50. A hydrolysate that simultaneously supports muscle retention and metabolic signalling could attract interest from manufacturers developing functional food and beverage products targeting those demographics.
Competitive Positioning
Marine protein hydrolysates occupy a niche but fast-growing corner of the sports and performance nutrition supply chain. Whey remains the dominant volume ingredient, but the category is under sustained pressure from consumers seeking novel protein sources, cleaner labels, and differentiated bioactivity. Clinical data published in peer-reviewed journals — particularly randomised, double-blind designs — materially strengthens a supplier's position in ingredient sourcing conversations with branded manufacturers and private-label retailers.
Hofseth BioCare, which processes byproducts from Norwegian salmon farming into high-value bioactive ingredients, has been building a clinical dossier around ProGo® over several years. The Biomedicines publication marks one of the more substantive data points in that effort, moving the ingredient from preclinical or observational backing toward controlled human trial evidence — a threshold that matters to regulatory affairs teams and formulators evaluating structure-function claims in key markets including the United States and the European Union.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
